Eli Lilly 過去の業績

過去基準チェック /56

Eli Lillyは、平均年間35.4%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間成長しています。収益は、平均年間9.4% 22.9%収益成長率で成長しています。 Eli Lillyの自己資本利益率は78.8%であり、純利益率は33.5%です。

主要情報

35.35%

収益成長率

35.60%

EPS成長率

Pharmaceuticals 業界の成長	16.25%
収益成長率	22.87%
株主資本利益率	78.84%
ネット・マージン	33.53%
次回の業績アップデート	29 Oct 2026

Recent updates

収支内訳

Eli Lilly の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

SNSE:LLYCL 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 26	79,666	26,711	12,237	14,596
31 Mar 26	72,249	25,277	11,560	14,113
31 Dec 25	65,179	20,640	11,094	13,337
30 Sep 25	59,420	18,412	10,618	12,559
30 Jun 25	53,258	13,800	9,976	11,827
31 Mar 25	49,004	11,106	9,226	11,202
31 Dec 24	45,043	10,590	8,594	10,991
30 Sep 24	40,863	8,370	7,633	10,531
30 Jun 24	38,923	7,342	7,337	10,206
31 Mar 24	35,932	6,138	7,144	9,851
31 Dec 23	34,124	5,240	7,404	9,313
30 Sep 23	32,073	4,988	6,682	8,747
30 Jun 23	29,516	6,498	6,515	8,140
31 Mar 23	27,691	5,687	6,236	7,566
31 Dec 22	28,541	6,245	6,068	7,191
30 Sep 22	29,240	6,033	6,037	7,093
30 Jun 22	29,071	5,692	6,020	6,996
31 Mar 22	29,323	6,129	6,104	6,869
31 Dec 21	28,318	5,582	6,142	6,931
30 Sep 21	27,759	5,972	6,119	6,870
30 Jun 21	26,726	6,071	6,069	6,631
31 Mar 21	25,486	6,093	5,867	6,366
31 Dec 20	24,540	6,194	5,869	5,976
30 Sep 20	23,214	5,573	6,019	5,829
30 Jun 20	22,950	5,618	5,924	5,745
31 Mar 20	23,087	5,533	6,048	5,757
31 Dec 19	22,320	4,638	6,004	5,595
30 Sep 19	21,843	4,264	5,984	5,405
30 Jun 19	21,673	4,103	6,019	5,305
31 Mar 19	21,622	2,545	5,913	5,174
31 Dec 18	21,493	3,151	5,735	5,051
30 Sep 18	22,016	372	5,855	5,146
30 Jun 18	22,368	-166	5,975	5,205
31 Mar 18	22,607	1,074	6,210	5,207
31 Dec 17	19,974	-86	5,733	5,096
30 Sep 17	22,471	2,225	6,475	5,321
30 Jun 17	22,005	2,447	6,526	5,217
31 Mar 17	21,585	2,187	6,483	5,281
31 Dec 16	21,222	2,738	6,330	5,310
30 Sep 16	20,837	2,444	6,460	5,238
30 Jun 16	20,605	2,466	6,471	5,145
31 Mar 16	20,179	2,319	6,483	4,978
31 Dec 15	19,959	2,408	6,533	4,796
30 Sep 15	19,704	2,359	6,535	4,538

質の高い収益: LLYCLは高品質の収益を持っています。

利益率の向上: LLYCLの現在の純利益率 (33.5%)は、昨年(25.9%)よりも高くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: LLYCLの収益は過去 5 年間で年間35.4%増加しました。

成長の加速: LLYCLの過去 1 年間の収益成長率 ( 93.6% ) は、5 年間の平均 ( 年間35.4%を上回っています。

収益対業界: LLYCLの過去 1 年間の収益成長率 ( 93.6% ) はPharmaceuticals業界11.7%を上回りました。

株主資本利益率

高いROE: LLYCLの自己資本利益率 ( 78.84% ) は抜群ですが、負債レベルが高いためこの指標は歪んでいます。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/09/10 07:01
終値	2026/09/08 00:00
収益	2026/06/30
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築したご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Eli Lilly and Company 28 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。53

アナリスト	機関
David Toung	Argus Research Company
Emily Field	Barclays
Kerry Holford	Berenberg

Eli Lilly 過去の業績

過去 基準チェック /56

主要情報

最近の業績更新

Second quarter 2026 earnings released: EPS: US$7.94 (vs US$6.30 in 2Q 2025)

First quarter 2026 earnings released: EPS: US$8.26 (vs US$3.07 in 1Q 2025)

Full year 2025 earnings released: EPS: US$22.95 (vs US$11.76 in FY 2024)

Eli Lilly and Company to Report Q4, 2025 Results on Feb 04, 2026

Third quarter 2025 earnings released: EPS: US$6.22 (vs US$1.08 in 3Q 2024)

Recent updates

Now 27% undervalued after recent price drop

Eli Lilly And Company Reports 52-Week Results From Together-PsO and TOGETHER-PSA Phase 3b Clinical Trials Evaluating Taltz And Zepbound Used Together in Adults with Psoriatic Disease and Obesity

Upcoming dividend of US$1.73 per share

Eli Lilly and Company Updates Earning Guidance for the Year 2026

Second quarter 2026 earnings released: EPS: US$7.94 (vs US$6.30 in 2Q 2025)

Now 25% undervalued

Eli Lilly and Company Receives Fda Breakthrough Therapy Designation for Olomorasib as Monotherapy for Previously Treated Kras G12c-Mutant Advanced Pancreatic Cancer

Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire AtaiBeckley Inc. (NasdaqGM:ATAI) from Apeiron Investment Group Limited and others for $2.6 billion.

Now 21% undervalued

First quarter dividend of US$1.73 announced

Eli Lilly And Company Receives Positive Opinion From CHMP For Jaypirca For Treatment Of Adults With Chronic Lymphocytic Leukemia Across All Lines Of Therapy

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Centessa Pharmaceuticals plc (NasdaqGS:CNTA) from Medicxi Ventures (UK) LLP, Index Ventures SA, General Atlantic Service Company, L.P. and other shareholders.

Eli Lilly and Company Declares Dividend for the Third Quarter of 2026, Payable on September 10, 2026

Eli Lilly and Company (NYSE:LLY) acquired 4E Therapeutics Inc.

Eli Lilly and Company Receives Fda Approval for EBGLYSS Maintenance Dose Every Eight Weeks in Patients with Moderate-To-Severe Atopic Dermatitis

Eli Lilly And Company Delivers Superior A1C Control And Weight Loss With Foundayo In Three Pivotal Type 2 Diabetes Trials

Eli Lilly And Company Announces Results From Phase 3 LIBRETTO-432 Clinical Trial Of Retevmo (Selpercatinib) As Adjuvant Therapy Versus Placebo In Patients With Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer

Eli Lilly and Company Presents New Data on Foundayo, Mounjaro and Retatrutide At the American Diabetes Association's 86Th Scientific Sessions

Eli Lilly and Company Announces Expanded Coverage for Foundayo and Zepbound Obesity Medicines

Eli Lilly and Company (NYSE:LLY) entered into an agreement to acquire Curevo, Inc. from HBM Healthcare Investments AG (SWX:HBMN), a fund managed by HBM Partners Ltd., and others for $1.5 billion.

Eli Lilly and Company Showcases Oncology Portfolio Across Tumor Types and Treatment Modalities At the American Society of Clinical Oncology Annual Meeting

Eli Lilly and Company Announces Results of Retatrutide Phase 3 Clinical Trial

Walden Macht Haran & Williams LLP Secures Victory Against Eli Lilly and Company

Eli Lilly and Company Presents Results for Foundayo and Zepbound in Weight Loss Maintenance Trials

New minor risk - Share price stability

First quarter dividend of US$1.73 announced

Eli Lilly and Company Announces Omvoh Demonstrates Durable Disease Clearance in Ulcerative Colitis Through Four Years

Eli Lilly and Company Raises Earning Guidance for the Year 2026

First quarter 2026 earnings released: EPS: US$8.26 (vs US$3.07 in 1Q 2025)

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire remaining majority stake in Ajax Therapeutics, Inc. for $2.3 billion.

Lilly Reportedly in Advanced Talks to Acquire Kelonia Therapeutics for over $2 Billion

Eli Lilly and Company Announces Positive Topline Results from Phase 3 Achieve-4 Trial Evaluating Foundayo (Orforglipron) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight At Increased Cardiovascular Risk

Eli Lilly And Company Announces Positive Phase 3 Results For Jaypirca (Pirtobrutinib) In Previously Treated CLL/SLL

Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S

Eli Lilly And Company Receives FDA Approval For Foundayo (Orforglipron) For Weight Loss

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Centessa Pharmaceuticals plc (NasdaqGS:CNTA) from Medicxi Ventures (UK) LLP, Index Ventures SA, General Atlantic Service Company, L.P. and other shareholders for $5.6 billion.

Eli Lilly and Company Presents Phase 3B Data on Taltz and Zepbound Combination for Adults with Psoriatic Arthritis and Obesity

Eli Lilly And Company Delivers Durable Disease Control With Ebglyss For Moderate-To-Severe Atopic Dermatitis

Insufficient new directors

Eli Lilly And Company Demonstrates Significant Reductions In A1C And Weight With Retatrutide In First Phase 3 Trial For Treatment Of Type 2 Diabetes

Eli Lilly And Company Announces Positive Phase 3 Results For EBGLYSS In Pediatric Patients With Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Company, Annual General Meeting, May 04, 2026

Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company Announce National Third-Party Payor Class Certified in Lawsuit Regarding Actos

Eli Lilly and Company Launches Employer Connect Platform with Tailored Obesity Coverage Options

Eli Lilly and Company's Olumiant Recommends by CHMP for Approval of Expanded Use in the European Union for Adolescents with Severe Alopecia Areata

Eli Lilly and Company Announces Detailed Results from ACHIEVE-3

Eli Lilly and Company Announces the U.S. Food and Drug Administration Approves a Label Expansion for Zepbound® (tirzepatide)

Eli Lilly and Company Presents New Long-Term Data from Eli Lilly and Company's Omvoh (mirikizumab-mrkz)

Eli Lilly and Company Announces Positive Topline Results from Taltz (Ixekizumab) and Zepbound (Tirzepatide)

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 LIBRETTO-432 Clinical Trial of Retevmo

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Orna Therapeutics, Inc. in a transaction valued at $2.4 billion.

Full year 2025 earnings released: EPS: US$22.95 (vs US$11.76 in FY 2024)

Eli Lilly and Company Provides Earnings Guidance for the Full Year 2026

Insufficient new directors

Eli Lilly and Company to Report Q4, 2025 Results on Feb 04, 2026

Eli Lilly and Company's Sofetabart Mipitecan Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Patients with Platinum-Resistant Ovarian Cancer

Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk

Eli Lilly and Company Announces Positive Topline Results from the Novel TOGETHER-PsA Open-Label Phase 3b Trial Evaluating the Concomitant Use of Taltz (Tirzepatide)

Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire Ventyx Biosciences, Inc. (NasdaqGS:VTYX) from New Science Ventures, LLC and others for approximately $1 billion.

Ventyx Biosciences Reportedly in $1 Billion Acquisition Talks with Eli Lilly

Celltrion, Inc. (KOSE:A068270) acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).

Eli Lilly and Company Announces Oral GLP-1 Orforglipron

Eli Lilly and Company Announces Positive Topline Results from the ATTAIN-MAINTAIN trial

Third quarter dividend of US$1.73 announced

Eli Lilly and Company Announces Updated Data for Lilly's Inluriyo™ (Imlunestrant) Reinforce Efficacy Results as Monotherapy and in Combination with Verzenio® (Abemaciclib) in Er+, Her2- Advanced Breast Cancer

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 TRIUMPH-4 Clinical Trial

Eli Lilly and Company Announces Results from the Phase 3 Bruin CLL-313 Clinical Trial of Jaypirca (Pirtobrutinib)

Insufficient new directors

Eli Lilly and Company Announces Results from the Phase 3 BRUIN CLL-314 Clinical Trial Evaluating Jaypirca (Pirtobrutinib

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Expanded Indication for Lilly's Jaypirca (Pirtobrutinib, 100 Mg & 50 Mg Tablets)

過去基準チェック /56